Go Pro
→ Why I went to Mount Rushmore (From Stansberry Research) (Ad)tc pixel Free BPCR Stock Alerts

BioPharma Credit (BPCR) Competitors

BioPharma Credit logo
GBX 0.97 +0.00 (+0.41%)
As of 11:59 AM Eastern
Compare

BPCR vs. FWT, BRIG, LGT, RIV, and SGEM

Should you buy BioPharma Credit stock or one of its competitors? BioPharma Credit's main competitors and comparable companies include Foresight Technology VCT (FWT), BlackRock Income and Growth (BRIG), Lighthouse Group (LGT), River and Mercantile Group (RIV), and ScotGems (SGEM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "asset management & custody banks" industry.

How does BioPharma Credit compare to Foresight Technology VCT?

Foresight Technology VCT (LON:FWT) and BioPharma Credit (LON:BPCR) are both small-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Foresight Technology VCT has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market. Comparatively, BioPharma Credit has a beta of 0.22688746, indicating that its share price is 77% less volatile than the broader market.

31.3% of BioPharma Credit shares are held by institutional investors. 0.3% of Foresight Technology VCT shares are held by insiders. Comparatively, 0.1% of BioPharma Credit shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Foresight Technology VCT's average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.

Company Overall Sentiment
Foresight Technology VCT Neutral
BioPharma Credit Neutral

Foresight Technology VCT has a net margin of 255.13% compared to BioPharma Credit's net margin of 92.62%. BioPharma Credit's return on equity of 11.29% beat Foresight Technology VCT's return on equity.

Company Net Margins Return on Equity Return on Assets
Foresight Technology VCT255.13% -4.85% 3.17%
BioPharma Credit 92.62%11.29%4.98%

BioPharma Credit has higher revenue and earnings than Foresight Technology VCT. Foresight Technology VCT is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Foresight Technology VCT£64K665.98£23.15M-£0.80N/A
BioPharma Credit£132.06M0.08£10.42B£11.400.09

Summary

BioPharma Credit beats Foresight Technology VCT on 8 of the 11 factors compared between the two stocks.

How does BioPharma Credit compare to BlackRock Income and Growth?

BlackRock Income and Growth (LON:BRIG) and BioPharma Credit (LON:BPCR) are both small-cap finance companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

BlackRock Income and Growth pays an annual dividend of GBX 7.70 per share and has a dividend yield of 3.3%. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 721.6%. BlackRock Income and Growth pays out 22.1% of its earnings in the form of a dividend. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, BlackRock Income and Growth had 3 more articles in the media than BioPharma Credit. MarketBeat recorded 3 mentions for BlackRock Income and Growth and 0 mentions for BioPharma Credit. BlackRock Income and Growth's average media sentiment score of 1.20 beat BioPharma Credit's score of 0.00 indicating that BlackRock Income and Growth is being referred to more favorably in the media.

Company Overall Sentiment
BlackRock Income and Growth Positive
BioPharma Credit Neutral

BioPharma Credit has a net margin of 92.62% compared to BlackRock Income and Growth's net margin of 88.25%. BlackRock Income and Growth's return on equity of 14.31% beat BioPharma Credit's return on equity.

Company Net Margins Return on Equity Return on Assets
BlackRock Income and Growth88.25% 14.31% 2.59%
BioPharma Credit 92.62%11.29%4.98%

0.7% of BlackRock Income and Growth shares are held by institutional investors. Comparatively, 31.3% of BioPharma Credit shares are held by institutional investors. 3.8% of BlackRock Income and Growth shares are held by company insiders. Comparatively, 0.1% of BioPharma Credit shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BioPharma Credit has higher revenue and earnings than BlackRock Income and Growth. BioPharma Credit is trading at a lower price-to-earnings ratio than BlackRock Income and Growth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BlackRock Income and Growth£7.07M6.04£6.90M£34.866.62
BioPharma Credit£132.06M0.08£10.42B£11.400.09

BlackRock Income and Growth has a beta of 0.628, suggesting that its stock price is 37% less volatile than the broader market. Comparatively, BioPharma Credit has a beta of 0.22688746, suggesting that its stock price is 77% less volatile than the broader market.

Summary

BlackRock Income and Growth beats BioPharma Credit on 9 of the 15 factors compared between the two stocks.

How does BioPharma Credit compare to Lighthouse Group?

Lighthouse Group (LON:LGT) and BioPharma Credit (LON:BPCR) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

In the previous week, Lighthouse Group's average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.

Company Overall Sentiment
Lighthouse Group Neutral
BioPharma Credit Neutral

31.3% of BioPharma Credit shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BioPharma Credit has a net margin of 92.62% compared to Lighthouse Group's net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat Lighthouse Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Lighthouse GroupN/A N/A N/A
BioPharma Credit 92.62%11.29%4.98%

Lighthouse Group pays an annual dividend of GBX 0.01 per share. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 721.6%. Lighthouse Group pays out 0.6% of its earnings in the form of a dividend. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

BioPharma Credit has higher revenue and earnings than Lighthouse Group. Lighthouse Group is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lighthouse Group£53.42M0.00N/A£1.80N/A
BioPharma Credit£132.06M0.08£10.42B£11.400.09

Summary

BioPharma Credit beats Lighthouse Group on 8 of the 10 factors compared between the two stocks.

How does BioPharma Credit compare to River and Mercantile Group?

River and Mercantile Group (LON:RIV) and BioPharma Credit (LON:BPCR) are both small-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

31.3% of BioPharma Credit shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

River and Mercantile Group pays an annual dividend of GBX 0.09 per share. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 721.6%. River and Mercantile Group pays out -4.1% of its earnings in the form of a dividend. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

BioPharma Credit has higher revenue and earnings than River and Mercantile Group. River and Mercantile Group is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
River and Mercantile Group£74.82M0.00N/A-£2.20N/A
BioPharma Credit£132.06M0.08£10.42B£11.400.09

In the previous week, River and Mercantile Group's average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.

Company Overall Sentiment
River and Mercantile Group Neutral
BioPharma Credit Neutral

BioPharma Credit has a net margin of 92.62% compared to River and Mercantile Group's net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat River and Mercantile Group's return on equity.

Company Net Margins Return on Equity Return on Assets
River and Mercantile GroupN/A N/A N/A
BioPharma Credit 92.62%11.29%4.98%

Summary

BioPharma Credit beats River and Mercantile Group on 9 of the 10 factors compared between the two stocks.

How does BioPharma Credit compare to ScotGems?

BioPharma Credit (LON:BPCR) and ScotGems (LON:SGEM) are both small-cap finance companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

BioPharma Credit has a net margin of 92.62% compared to ScotGems' net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat ScotGems' return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit92.62% 11.29% 4.98%
ScotGems N/A N/A N/A

31.3% of BioPharma Credit shares are held by institutional investors. 0.1% of BioPharma Credit shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BioPharma Credit has higher revenue and earnings than ScotGems. ScotGems is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£132.06M0.08£10.42B£11.400.09
ScotGems£5.07M0.00N/A£0.07N/A

In the previous week, BioPharma Credit's average media sentiment score of 0.00 equaled ScotGems'average media sentiment score.

Company Overall Sentiment
BioPharma Credit Neutral
ScotGems Neutral

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 721.6%. ScotGems pays an annual dividend of GBX 4 per share. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. ScotGems pays out 5,714.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

BioPharma Credit beats ScotGems on 9 of the 10 factors compared between the two stocks.

Get BioPharma Credit News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPCR vs. The Competition

Export
MetricBioPharma CreditCapital Markets IndustryFinance SectorLON Exchange
Market Cap£10.89M£5.35B£13.94B£2.87B
Dividend Yield7.20%7.51%5.96%6.26%
P/E Ratio0.0929.8425.21366.50
Price / Sales0.081,232.31508.1590,135.34
Price / Cash1.1947.8139.9227.89
Price / Book0.013.502.726.34
Net Income£10.42B£417.39M£1.31B£5.89B
7 Day PerformanceN/A-1.35%-0.95%-0.17%
1 Month Performance-1.22%-2.91%-1.31%-0.47%
1 Year Performance6.59%3.88%9.52%20.13%

BioPharma Credit Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPCR
BioPharma Credit
N/AGBX 0.97
+0.4%		N/A+5.9%£10.89M£132.06M0.09N/A
FWT
Foresight Technology VCT
N/AGBX 85.50
-2.3%		N/AN/A£42.62M£64KN/A375
BRIG
BlackRock Income and Growth
N/AGBX 230
-4.2%		N/A+13.9%£42.59M£7.07M6.60N/A
LGT
Lighthouse Group
N/AN/AN/AN/A£42.46M£53.42M18.47156
RIV
River and Mercantile Group
N/AN/AN/AN/A£42.40M£74.82MN/A300

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:BPCR) was last updated on 9/16/2026 by MarketBeat.com Staff.
From Our Partners
Your backdoor link (still works)
Bill Poulos is offering a private link to download his book Simple Options Trading For Beginners, bypassing th...
Profits Run | Sponsoredtc pixel
I don't write about politics. Until today.
Polls have favored a House flip all summer, and forecasters now expect Washington to change hands in November....
American Alternative | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
The national debt just passed $39 trillion
The U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...
US Gold Bureau | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
A new kind of civil war is coming after election day?
Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...
Stansberry Research | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
MILLIONAIRE MASTERCLASS INVITE: Altucher
James Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...
Paradigm Press | Sponsoredtc pixel